Portfolio overlap

ASD / IHE

Overlap	Shared positions
14.31%	7

Defiance Autism Impact ETF

Report dates 06/30/2026 | 99.83% NAV

Overlap / ASD 19.57%

iShares U.S. Pharmaceutical ETF

Report dates 06/30/2026 | 99.92% NAV

Overlap / IHE 58.48%

Largest shared positions

Security	ASD	IHE	Overlap
Johnson & Johnson	2.59%	22.44%	2.59%
Jazz Pharmaceuticals PLC	2.50%	3.45%	2.50%
Eli Lilly & Co	2.49%	22.25%	2.49%

Weights are percentages of each fund's net assets. Shared weight is the sum of the smallest weight per matched common-stock class. Unmatched positions are excluded without renormalizing the weights.

History





1 matched portfolio dates from 06/30/2026 to 06/30/2026. Both filings use the same portfolio date. The minimum matched share of net assets is 99.83%. The filing dates are 55–59 days after the portfolio dates. This is filing lag. The archive does not establish an exact intraday release time.

Largest changes

Only one comparable date is available.

Sources and methodology

Weights are percentages of each fund's net assets. Shared weight is the sum of the smallest weight per matched common-stock class. Unmatched positions are excluded without renormalizing the weights.

nport-common-equity-v1

Report dates	Weight (%)	Classes	ASD · SEC	IHE · SEC
06/30/2026	14.31%	7	0001193125-26-373330	0001004726-26-007042